REAL-WORLD CLINICAL AND ECONOMIC OUTCOMES OF THERAPIES FOR TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA IN CHINESE PATIENTS: A RETROSPECTIVE ANALYSIS
Author(s)
Jiawen You, MM1, Yuanyuan Zhang, MM1, Yuan Meng, MM1, Haijun Sun, MM1, Jiayi Wang, MM1, Xiaojun Liu, MD, PhD2, Jianbo Meng, MD, PhD1, Yuting Chen, MS3, Wendong Chen, PhD, MD4.
1The Third Hospital of Hebei Medical University, Shijiazhuang, China, 2The Second Hospital of Hebei Medical University, Shijiazhuang, China, 3Changsha Nuomin Medical Technology Ltd, Changsha, China, 4Normin Health Consulting, Mississauga, ON, Canada.
1The Third Hospital of Hebei Medical University, Shijiazhuang, China, 2The Second Hospital of Hebei Medical University, Shijiazhuang, China, 3Changsha Nuomin Medical Technology Ltd, Changsha, China, 4Normin Health Consulting, Mississauga, ON, Canada.
OBJECTIVES: To evaluate real-world clinical and economic outcomes among transplant-eligible patients with newly diagnosed multiple myeloma (NDMM) in China, comparing those who received autologous stem cell transplantation (ASCT) with those who did not.
METHODS: This multicenter retrospective cohort study analyzed data from NDMM patients treated between 2021 and 2025 at two Chinese tertiary hospitals. Patients were stratified into ASCT and non-ASCT groups. Demographics, treatment patterns, progression-free survival (PFS), healthcare resource utilization (HRU), and direct medical costs were extracted from electronic medical records and billing databases. Propensity score matching (PSM) balanced baseline covariates between the two groups. PFS were compared using Kaplan-Meier analysis and multivariate Cox proportional hazards regression. A subgroup analysis evaluated differences in the measured outcomes between single and tandem ASCT.
RESULTS: From an initial cohort of 125 patients, PSM generated 44 matched pairs. The ASCT group demonstrated a significantly longer median PFS than the non-ASCT group (3.42 vs. 1.89 years; P =0.001). Multivariate Cox regression confirmed that ASCT was associated with a reduced risk of disease progression (hazard ratio: 0.412; P = 0.015). While total costs and outpatient visits were comparable between the two groups, the non-ASCT group utilized more inpatient resources, experiencing more frequent annual hospitalizations (8.7 vs. 5.3; P < 0.001) and longer total hospital stays (129.6 vs. 108.8 days; P = 0.049). Subgroup analysis revealed no significant differences in PFS, HRU, or direct medical costs between single and tandem ASCT.
CONCLUSIONS: ASCT for transplant-eligible NDMM was associated with prolonged PFS and lower inpatient resource use without increasing total costs in Chinese patients. Tandem ASCT did not show clear advantages over single ASCT.
METHODS: This multicenter retrospective cohort study analyzed data from NDMM patients treated between 2021 and 2025 at two Chinese tertiary hospitals. Patients were stratified into ASCT and non-ASCT groups. Demographics, treatment patterns, progression-free survival (PFS), healthcare resource utilization (HRU), and direct medical costs were extracted from electronic medical records and billing databases. Propensity score matching (PSM) balanced baseline covariates between the two groups. PFS were compared using Kaplan-Meier analysis and multivariate Cox proportional hazards regression. A subgroup analysis evaluated differences in the measured outcomes between single and tandem ASCT.
RESULTS: From an initial cohort of 125 patients, PSM generated 44 matched pairs. The ASCT group demonstrated a significantly longer median PFS than the non-ASCT group (3.42 vs. 1.89 years; P =0.001). Multivariate Cox regression confirmed that ASCT was associated with a reduced risk of disease progression (hazard ratio: 0.412; P = 0.015). While total costs and outpatient visits were comparable between the two groups, the non-ASCT group utilized more inpatient resources, experiencing more frequent annual hospitalizations (8.7 vs. 5.3; P < 0.001) and longer total hospital stays (129.6 vs. 108.8 days; P = 0.049). Subgroup analysis revealed no significant differences in PFS, HRU, or direct medical costs between single and tandem ASCT.
CONCLUSIONS: ASCT for transplant-eligible NDMM was associated with prolonged PFS and lower inpatient resource use without increasing total costs in Chinese patients. Tandem ASCT did not show clear advantages over single ASCT.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
CO31
Topic
Clinical Outcomes, Economic Evaluation, Real World Data & Information Systems
Topic Subcategory
Comparative Effectiveness or Efficacy
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Oncology